Oxnard G - Search Results

1

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.

Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA. Van Allen EM, et al. Among authors: oxnard g. Cancer Immunol Res. 2015 Aug;3(8):855-63. doi: 10.1158/2326-6066.CIR-15-0024. Epub 2015 May 26. Cancer Immunol Res. 2015. PMID: 26014096 Free PMC article.

2

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.

Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. Oxnard GR, et al. Clin Cancer Res. 2011 Sep 1;17(17):5530-7. doi: 10.1158/1078-0432.CCR-10-2571. Epub 2011 Jul 20. Clin Cancer Res. 2011. PMID: 21775534 Free PMC article. Review.

3

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.

Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Oxnard GR, et al. Clin Cancer Res. 2011 Oct 1;17(19):6322-8. doi: 10.1158/1078-0432.CCR-11-1080. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831955 Free PMC article.

4

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.

He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Jänne PA, Ladanyi M, Oxnard GR. He M, et al. Among authors: oxnard gr. Clin Cancer Res. 2012 Mar 15;18(6):1790-7. doi: 10.1158/1078-0432.CCR-11-2361. Epub 2011 Dec 21. Clin Cancer Res. 2012. PMID: 22190593 Free PMC article.

5

KRAS wild-type lung cancer: a moving target in an era of genotype migration.

Oxnard GR, Jänne PA. Oxnard GR, et al. J Clin Oncol. 2012 Sep 20;30(27):3322-4. doi: 10.1200/JCO.2012.43.2740. Epub 2012 Aug 6. J Clin Oncol. 2012. PMID: 22869875 No abstract available.

6

When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH. Oxnard GR, et al. J Natl Cancer Inst. 2012 Oct 17;104(20):1534-41. doi: 10.1093/jnci/djs353. Epub 2012 Aug 27. J Natl Cancer Inst. 2012. PMID: 22927506 Free PMC article.

7

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA. Oxnard GR, et al. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18. J Thorac Oncol. 2013. PMID: 23328547 Free PMC article.

8

New targetable oncogenes in non-small-cell lung cancer.

Oxnard GR, Binder A, Jänne PA. Oxnard GR, et al. J Clin Oncol. 2013 Mar 10;31(8):1097-104. doi: 10.1200/JCO.2012.42.9829. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401445 Free PMC article. Review.

9

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.

Oxnard GR, Jänne PA. Oxnard GR, et al. Clin Cancer Res. 2013 Apr 1;19(7):1634-6. doi: 10.1158/1078-0432.CCR-13-0169. Epub 2013 Feb 12. Clin Cancer Res. 2013. PMID: 23403632 Free PMC article.

10

Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Brunner AM, et al. J Thorac Oncol. 2013 Nov;8(11):1434-7. doi: 10.1097/JTO.0b013e3182a47162. J Thorac Oncol. 2013. PMID: 24128713 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page